EHBP1L1 and neoplasm: Further analysis showed that although both EHBP1L1 siRNA and anti‐PD‐1 monotherapy inhibited tumor growth and prolonged OS, siEHBP1L1 and PD‐1 blockade combination therapy remarkably reduced tumor burden and improved OS compared to treatment with siEHBP1L1 or anti‐PD‐1 antibody alone (Figure 7C–F).